1. Asundexian versus Apixaban in Patients with Atrial Fibrillation. The New England Journal of Medicine (NEJM) 2025.  OCEANIC-AF Steering Committee and Investigators: From Norway John Munkhaugen, Drammen sykehus, MED/NORCOR.
  2. Statin adherence in coronary outpatients: The relationship between a novel blood test and pharmacy registry data. Atherosclerosis 2025
  3. Hvordan kan vi hjelpe hjertepasienten med livsstilsendringer i 2024? Hjerteforum N° 1/ 2025/ vol 38 (s. 108-112). Fagartikkel.
  4. The effects of cognitive behavioral therapy for insomnia in patients with cardiovascular disease: a systematic review and meta-analysis. Journal of Clinical Sleep Medicine 2025
  5. Low-Density Lipoprotein Cholesterol Increases Significantly During Brief Discontinuation of Atorvastatin and Correlates With Metabolite Half-Lives. Pharmacology Research & Perspectives 2025
  6. More musculoskeletal disorders and poor pain management in patients with familial hypercholesterolemia and self-perceived side effects to cholesterol-lowering treatment. Posterpresentasjon. Internasjonal konferanse ESC Preventive Cardiology 2025, Milan Italy.
  7. Potential benefits of group cognitive-behavioural therapy for insomnia in patients with coronary heart disease versus usual care: an early economic evaluation. Posterpresentasjon. Internasjonal konferanse ESC Preventive Cardiology 2025, Milan Italy.
  8. Motivational smoking cessation counselling with proactive referral to community-based follow-up after hospitalisation for vascular disease: a pragmatic, randomised trial. Posterpresentasjon. Internasjonal konferanse ESC Preventive Cardiology 2025, Milan Italy.
  9. Clinical and psychosocial predictors of long-term smoking cessation in patients with atherosclerotic vascular disease: a pre-specified analysis of two randomised trials. Posterpresentasjon. Internasjonal konferanse ESC Preventive Cardiology 2025, Milan Italy.
  10. Integration of psychological risk modifiers on-top the SMART2-risk score for estimation of recurrent cardiovascular events in patients with atherosclerotic cardiovascular disease. European Journal of Preventive Cardiology, 2025
  11. Experiences of the attention training technique delivered in groups as treatment for anxiety and depression in patients with coronary heart disease: a qualitative study. BMC Psychiatry, 2025
  12. Psychological factors beyond the SMART2 model for predicting recurrent events in atherosclerotic cardiovascular disease patients. European Journal of Preventive Cardiology, 2025
  13. Secondary prevention programs provided to patients following myocardial infarction in Norway. A national survey. European Journal of Cardiovascular Nursing, Issue Supplement_1, 2025
  14. Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. The New England Journal of Medicine, 2025.
  15. β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials. The Lacet, 2025.
  16. Motivational smoking cessation counselling and community-based follow-up after hospitalisation for vascular disease:  a randomised controlled trial. Addiction, 2025
  17. Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. New England Journal of Medicine, 2025
  18. Potential benefits of group cognitive-behavioural therapy for insomnia in outpatients with coronary heart disease versus usual care: An early economic evaluation. BMJ Open, 2025.
  19. Sekundærforebygging hos hjerteinfarktpasienter med kjent koronarsykdom. Tidsskrift for den norske legeforening, 2025
  20. Skal vi fortsatt gi betablokker etter hjerteinfarkt? Hjerteforum N° 4/ 2025/ vol 38 (s. 57-59). Fagartikkel.
  21. Evaluation of a novel blood test to monitor statin treatment in cardiovascular disease prevention. Doktoravhandling 2025 av Jonas Pivoriunas